{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T17:46:30Z","timestamp":1790012790373,"version":"4.0.1"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100020841","name":"Envision","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020841","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Neuroimmunology"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.jneuroim.2026.578925","type":"journal-article","created":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T15:23:56Z","timestamp":1774970636000},"page":"578925","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Real-world experience with switching from intravenous immunoglobulin to subcutaneous efgartigimod PH20 in patients with chronic inflammatory demyelinating polyradiculoneuropathy: A case series"],"prefix":"10.1016","volume":"417","author":[{"given":"Raghav","family":"Govindarajan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jneuroim.2026.578925_bb0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2019.116497","article-title":"Immunoglobulin administration for the treatment of CIDP: IVIG or SCIG?","volume":"408","author":"Allen","year":"2020","journal-title":"J. Neurol. Sci."},{"issue":"1","key":"10.1016\/j.jneuroim.2026.578925_bb0010","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1007\/s12325-020-01540-6","article-title":"A global survey of disease burden in patients who carry a diagnosis of chronic inflammatory demyelinating polyneuropathy","volume":"38","author":"Allen","year":"2021","journal-title":"Adv. Ther."},{"issue":"10","key":"10.1016\/j.jneuroim.2026.578925_bb0015","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/S1474-4422(24)00309-0","article-title":"Safety, tolerability, and efficacy of subcutaneous efgartigimod in patients with chronic inflammatory demyelinating polyradiculoneuropathy (ADHERE): a multicentre, randomised-withdrawal, double-blind, placebo-controlled, phase 2 trial","volume":"23","author":"Allen","year":"2024","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.jneuroim.2026.578925_bb0020","author":"American Association of Neuromuscular & Electrodiagnostic Medicine"},{"issue":"Suppl. 1","key":"10.1016\/j.jneuroim.2026.578925_bb0025","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/cei.12518","article-title":"Adverse effects of immunoglobulin G therapy: thromboembolism and haemolysis","volume":"178","author":"Bonilla","year":"2014","journal-title":"Clin. Exp. Immunol."},{"issue":"1","key":"10.1016\/j.jneuroim.2026.578925_bb0030","doi-asserted-by":"crossref","DOI":"10.1111\/ene.16098","article-title":"Effect of efgartigimod on muscle group subdomains in participants with generalized myasthenia gravis: post hoc analyses of the phase 3 pivotal ADAPT study","volume":"31","author":"Bril","year":"2024","journal-title":"Eur. J. Neurol."},{"issue":"10413","key":"10.1016\/j.jneuroim.2026.578925_bb0035","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1016\/S0140-6736(23)01460-5","article-title":"Efficacy and safety of the neonatal Fc receptor inhibitor efgartigimod in adults with primary immune thrombocytopenia (ADVANCE IV): a multicentre, randomised, placebo-controlled, phase 3 trial","volume":"402","author":"Broome","year":"2023","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.jneuroim.2026.578925_bb0040","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.1468-1331.2009.02802.x","article-title":"A nationwide retrospective analysis on the effect of immune therapies in patients with chronic inflammatory demyelinating polyradiculoneuropathy","volume":"17","author":"Cocito","year":"2010","journal-title":"Eur. J. Neurol."},{"issue":"11\u221212","key":"10.1016\/j.jneuroim.2026.578925_bb0045","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1080\/14737175.2022.2169134","article-title":"Intravenous immunoglobulin in chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): mechanisms of action and clinical and genetic considerations","volume":"22","author":"Dalakas","year":"2022","journal-title":"Expert. Rev. Neurother."},{"key":"10.1016\/j.jneuroim.2026.578925_bb0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2024.123264","article-title":"Post-hoc analyses from the ADAPT clinical study demonstrate aggregate sustained benefit of efgartigimod in generalized myasthenia gravis","volume":"466","author":"Dewilde","year":"2024","journal-title":"J. Neurol. Sci."},{"issue":"6","key":"10.1016\/j.jneuroim.2026.578925_bb0055","doi-asserted-by":"crossref","first-page":"3462","DOI":"10.1007\/s00415-024-12293-5","article-title":"Real-world experience with efgartigimod in patients with myasthenia gravis","volume":"271","author":"Fuchs","year":"2024","journal-title":"J. Neurol."},{"issue":"6","key":"10.1016\/j.jneuroim.2026.578925_bb0060","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1177\/1756285612457215","article-title":"An update on the management of chronic inflammatory demyelinating polyneuropathy","volume":"5","author":"Gorson","year":"2012","journal-title":"Ther. Adv. Neurol. Disord."},{"issue":"4","key":"10.1016\/j.jneuroim.2026.578925_bb0065","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1111\/j.1529-8027.2010.00284.x","article-title":"Chronic inflammatory demyelinating polyneuropathy disease activity status: recommendations for clinical research standards and use in clinical practice","volume":"15","author":"Gorson","year":"2010","journal-title":"J. Peripher. Nerv. Syst."},{"issue":"3","key":"10.1016\/j.jneuroim.2026.578925_bb0070","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1002\/mus.27356","article-title":"Subcutaneous immunoglobulin treatment for chronic inflammatory demyelinating polyneuropathy","volume":"64","author":"Goyal","year":"2021","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.jneuroim.2026.578925_bb0080","article-title":"Long-term safety, tolerability, and efficacy of efgartigimod (ADAPT+): interim results from a phase 3 open-label extension study in participants with generalized myasthenia gravis","volume":"14","author":"Howard","year":"2023","journal-title":"Front. Neurol."},{"issue":"7","key":"10.1016\/j.jneuroim.2026.578925_bb0075","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/S1474-4422(21)00159-9","article-title":"Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial","volume":"20","author":"Howard","year":"2021","journal-title":"Lancet Neurol."},{"issue":"5","key":"10.1016\/j.jneuroim.2026.578925_bb0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.neurot.2024.e00378","article-title":"Subcutaneous efgartigimod PH20 in generalized myasthenia gravis: a phase 3 randomized noninferiority study (ADAPT-SC) and interim analyses of a long-term open-label extension study (ADAPT-SC+)","volume":"21","author":"Howard","year":"2024","journal-title":"Neurotherapeutics"},{"issue":"5","key":"10.1016\/j.jneuroim.2026.578925_bb0090","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1002\/mus.27974","article-title":"Safety and outcomes with efgartigimod use for acetylcholine receptor-positive generalized myasthenia gravis in clinical practice","volume":"68","author":"Katyal","year":"2023","journal-title":"Muscle Nerve"},{"issue":"6","key":"10.1016\/j.jneuroim.2026.578925_bb0095","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.3390\/biomedicines12061214","article-title":"Real-world case series of efgartigimod for Japanese generalized myasthenia gravis: well-tailored treatment cycle intervals contribute to sustained symptom control","volume":"12","author":"Konno","year":"2024","journal-title":"Biomedicines"},{"key":"10.1016\/j.jneuroim.2026.578925_bb0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2024.123313","article-title":"Early deterioration of CIDP following transition from IVIG to FcRn inhibitor treatment","volume":"468","author":"Levine","year":"2025","journal-title":"J. Neurol. Sci."},{"issue":"8","key":"10.1016\/j.jneuroim.2026.578925_bb0105","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1002\/acn3.52142","article-title":"Efgartigimod for generalized myasthenia gravis: a multicenter real-world cohort study in China","volume":"11","author":"Luo","year":"2024","journal-title":"Ann. Clin. Transl. Neurol."},{"issue":"9","key":"10.1016\/j.jneuroim.2026.578925_bb0110","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1136\/jnnp-2014-309697","article-title":"Chronic inflammatory demyelinating polyradiculoneuropathy: from pathology to phenotype","volume":"86","author":"Mathey","year":"2015","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"8","key":"10.1016\/j.jneuroim.2026.578925_bb0115","article-title":"Plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy","volume":"2015","author":"Mehndiratta","year":"2015","journal-title":"Cochrane Database Syst. Rev."},{"issue":"6","key":"10.1016\/j.jneuroim.2026.578925_bb0120","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.3111\/13696998.2012.716804","article-title":"Patient and parent preferences for immunoglobulin treatments: a conjoint analysis","volume":"15","author":"Mohamed","year":"2012","journal-title":"J. Med. Econ."},{"key":"10.1016\/j.jneuroim.2026.578925_bb0125","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2024.1472845","article-title":"Efgartigimod treatment for generalized myasthenia gravis: a single-center case series of 16 patients","volume":"15","author":"Nomura","year":"2024","journal-title":"Front. Neurol."},{"issue":"10","key":"10.1016\/j.jneuroim.2026.578925_bb0130","doi-asserted-by":"crossref","first-page":"3706","DOI":"10.1007\/s00415-020-09998-8","article-title":"Systematic literature review of burden of illness in chronic inflammatory demyelinating polyneuropathy (CIDP)","volume":"268","author":"Querol","year":"2021","journal-title":"J. Neurol."},{"issue":"3","key":"10.1016\/j.jneuroim.2026.578925_bb0135","doi-asserted-by":"crossref","DOI":"10.1111\/jns.70047","article-title":"Real-world multinational survey of chronic inflammatory demyelinating polyneuropathy: disease characteristics and therapeutic landscape","volume":"30","author":"Querol","year":"2025","journal-title":"J. Peripher. Nerv. Syst."},{"key":"10.1016\/j.jneuroim.2026.578925_bb0140","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2024.1486659","article-title":"Efgartigimod treatment in patients with anti-MuSK-positive myasthenia gravis in exacerbation","volume":"15","author":"Shi","year":"2024","journal-title":"Front. Neurol."},{"issue":"2","key":"10.1016\/j.jneuroim.2026.578925_bb0145","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1002\/mus.27046","article-title":"Chronic inflammatory demyelinating polyradiculoneuropathy-diagnostic pitfalls and treatment approach","volume":"63","author":"Stino","year":"2021","journal-title":"Muscle Nerve"},{"issue":"10","key":"10.1016\/j.jneuroim.2026.578925_bb0150","doi-asserted-by":"crossref","first-page":"4372","DOI":"10.1172\/JCI97911","article-title":"Neonatal Fc receptor antagonist Efgartigimod safely and sustainably reduces IgGs in humans","volume":"128","author":"Ulrichts","year":"2018","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.jneuroim.2026.578925_bb0155","series-title":"Highlights of Prescribing Information","article-title":"VYVGART HYTRULO (Efgartigimod Alfa and hyaluronidase-QVFC) injection, for subcutaneous use","author":"US Food and Drug Administration","year":"2024"},{"key":"10.1016\/j.jneuroim.2026.578925_bb0160","series-title":"Highlights of Prescribing Information","article-title":"VYVGART HYTRULO (Efgartigimod Alfa and hyaluronidase-QVFC) injection, for subcutaneous use","author":"US Food and Drug Administration","year":"2025"},{"issue":"11","key":"10.1016\/j.jneuroim.2026.578925_bb0165","doi-asserted-by":"crossref","first-page":"3556","DOI":"10.1111\/ene.14959","article-title":"European Academy of neurology\/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force \u2013 second revision","volume":"28","author":"Van den Bergh","year":"2021","journal-title":"Eur. J. Neurol."}],"container-title":["Journal of Neuroimmunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165572826000731?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165572826000731?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T12:55:46Z","timestamp":1784552146000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165572826000731"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":33,"alternative-id":["S0165572826000731"],"URL":"https:\/\/doi.org\/10.1016\/j.jneuroim.2026.578925","relation":{},"ISSN":["0165-5728"],"issn-type":[{"value":"0165-5728","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world experience with switching from intravenous immunoglobulin to subcutaneous efgartigimod PH20 in patients with chronic inflammatory demyelinating polyradiculoneuropathy: A case series","name":"articletitle","label":"Article Title"},{"value":"Journal of Neuroimmunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jneuroim.2026.578925","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"578925"}}